中科院深圳先進(jìn)技術(shù)科學(xué)院接受客座學(xué)生專業(yè)

1、中國(guó)科學(xué)院深圳先進(jìn)技術(shù)研究院導(dǎo)師簡(jiǎn)況表導(dǎo)師姓名萬(wàn)曉春性別男職稱研究員專業(yè)名稱免疫學(xué)導(dǎo)師類別博導(dǎo) 碩導(dǎo)所在單元醫(yī)藥所抗體藥物研究中心是否兼職是 否招生專業(yè)物理化學(xué)（含化學(xué)物理）生物化學(xué)與分子生物學(xué)信號(hào)與信息處理模式識(shí)別與智能系統(tǒng)計(jì)算機(jī)應(yīng)用技術(shù)材料工程電子與通信工程控制工程計(jì)算機(jī)技術(shù)生物工程研究方向抗體藥物研發(fā)免疫細(xì)胞信號(hào)傳導(dǎo)炎癥/自身免疫性疾病及癌癥的治療在研課題無(wú)。個(gè)人簡(jiǎn)歷萬(wàn)曉春研究員畢業(yè)于加拿大蒙特利爾大學(xué)醫(yī)學(xué)院，在世界首次成功研制抗EPHRIN家族成員的單抗和多抗試劑，引起多家公司的關(guān)注，并在類風(fēng)濕關(guān)節(jié)炎、肝炎等多種疾病模型試驗(yàn)中有重大發(fā)現(xiàn)，獲得加拿大國(guó)家健康研究院（CIHR）優(yōu)秀研究員獎(jiǎng)

2、。萬(wàn)曉春研究員具有多年在GLP實(shí)驗(yàn)室條件下臨床及臨床前的研究經(jīng)歷，具有在CRO GLP實(shí)驗(yàn)室進(jìn)行抗體和臨床樣品分析，免疫學(xué)方法研發(fā)和驗(yàn)證的經(jīng)驗(yàn)，對(duì)抗體藥物的PD/ PK藥物檢測(cè)和臨床藥物分析具有豐富的經(jīng)驗(yàn)。萬(wàn)曉春研究員近些年來(lái)分別在賓夕法尼亞大學(xué)、Eisai、Merck及 Frontagelab等美國(guó)一流的科研與大型制藥公司以高級(jí)研究員從事單抗藥物的研發(fā)工作，曾與美國(guó)大型生物制藥公司 HUMAN GENOME SCIENCE公司合作研究DcR3基因在免疫系統(tǒng)中的作用，首次在世界上成功研制DcR3 的廣譜癌癥檢測(cè)系統(tǒng)（ELISA 試劑盒），在癌癥檢測(cè)及監(jiān)測(cè)上有重大意義。主要科研成果及所獲榮譽(yù)1.

3、 Wan X, Shi G, Semenuk M, Zhang J, and Wu J. DcR3/TR6 modulates immune cell interactions. J Cell Biochem. 2003 Jun 1; 89(3): 603-122. Wan X*, Zhang J*, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P and Wu J. A TNF family member LIGHT transduces costimulatory signals into human T cells. J Immunol. 2002

4、Dec 15;169 (12):6813-21(*equal contribution)3. Shi G, H Luo, Wan X, J Zhang and Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood. 2002 Nov 1;100 (9):3279-864. Wan X*, Zhang J*, Salcedo TW*, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, Li Y, Moore

5、 PA, and Wu J. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin. Invest. 2001 Jun;107(11):1459-68 (*equal contributors)5. Luo H, Wan X, Wu Y, and Wu J. Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells. J Immunol 2001 Aug 1;167(3):1362-706. Luo H

6、, Wu Y, Qi S, Wan X, Chen H, and Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001 Jul 27;72(2):196-2027. Chen H, Xu D, Luo H, Loubeau M, Wan X, Peng J, Qi S, Daloze P, Fritzsimmons W E, Bersky I, Peets J, Sehgal S N, and Wu J. Compromised renal

7、graft rejection response in Vervet monkeys after withdrawal of immunosuppressants Prograf and Sirolimus. Transplantation 69:1555-1561, 2000其他2004-2007 加拿大健康研究院優(yōu)秀研究員獎(jiǎng)2005 臨床免疫學(xué)會(huì)聯(lián)合會(huì)會(huì)議摘要和旅行獎(jiǎng)聯(lián)系方式郵箱xc.wan電人主頁(yè)備注NameXiaochun WanPositionsexecutive director of the centreAcademic titleprofessorE-

8、mailxc.wanPhonersonal WebsiteResume Dr. Wan was graduated from the medical school of University of Montreal. He is the first scientist in the world who was succeeded in developing the anti-EPHRIN monoclonal antibodies and polyclonal antibodies. He also made some important discoveries in

9、 a variety of disease models such as rheumatoid arthritis and hepatitis and won the scholar award of Canadian Institute of Health Research (CIHR). He has many years of experience on the research and development of therapeutic antibody drugs and investigation of autoimmune diseases. Dr Wan has more t

10、han six years of GLP research experience in clinical and preclinical laboratories and experience of antibody and clinical samples analysis in CRO GLP laboratory. He is also an expert on PD/PK antibody drugs and clinical drug analysis. Dr Wan had been working in the University of Pennsylvania, severa

11、l well-known pharmaceutical companies such as Eisai, Merck, Frontagelab in the past years. He had been working with HUMAN GENOME SCIENCE biopharmaceutical corporation in studying the role of DcR3 in immune system. He was the first investigator in developing a DcR3 ELISA kit (a broad spectrum of canc

12、er detection system) that has great significance in cancer detection and surveillance.DirectionTherapeutic antibody developmentimmune cell signalingAutoimmune/inflammation and cancer therapyAchievements2004-2007 Canadian Institute of Health Research (CIHR) Scholar Award2005Abstract and travel award,

13、 Federation of clinical immunologist Societies (FOCIS) ConferenceArticle1. Wan X, Shi G, Semenuk M, Zhang J, and Wu J. DcR3/TR6 modulates immune cell interactions. J Cell Biochem. 2003 Jun 1; 89(3): 603-122. Wan X*, Zhang J*, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P and Wu J. A TNF family member L

14、IGHT transduces costimulatory signals into human T cells. J Immunol. 2002 Dec 15;169 (12):6813-21(*equal contribution)3. Shi G, H Luo, Wan X, J Zhang and Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood. 2002 Nov 1;100 (9):3279-864. Wan X*, Zhang J*, Salcedo T

15、W*, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, Li Y, Moore PA, and Wu J. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin. Invest. 2001 Jun;107(11):1459-68 (*equal contributors)5. Luo H, Wan X, Wu Y, and Wu J. Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells. J Immunol 2001 Aug 1;167(3):1362-706. Luo H, Wu Y, Qi S, Wan X, Chen H, and Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001 Jul 27;72(2):196-2027. Chen H, Xu D, Luo H, Loubeau